THE PROIMMUNE COMPANY L.L.C. – Trademark Portfolio
Entity Type: 16
THE PROIMMUNE COMPANY L.L.C. holds 10 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 10 filings in this category. The portfolio also extends into Class 32 (Light Beverages) across 2 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include IMMUNE DRINK, VITAMIN GSH-S, and IMMUNE FORMULATION 200. The owner is based in BROOKLYN HEIGHTS, NY.
77 REMSEN STREET
BROOKLYN HEIGHTS, NY 11201
Showing of trademarks Trademarks
Trademark Classifications
THE PROIMMUNE COMPANY L.L.C.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Beers; mineral and aerated waters and other non-alcoholic beverages; fruit beverages
Frequently Asked Questions
How many trademarks does THE PROIMMUNE COMPANY L.L.C. have?
THE PROIMMUNE COMPANY L.L.C. has 10 U.S. trademarks filed with the USPTO. Of these, 3 registered, 7 abandoned.
What trademark classes does THE PROIMMUNE COMPANY L.L.C. file in?
THE PROIMMUNE COMPANY L.L.C. files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 32 (Light Beverages). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are THE PROIMMUNE COMPANY L.L.C.'s most well-known trademarks?
THE PROIMMUNE COMPANY L.L.C.'s registered trademark portfolio includes well-known marks such as IMMUNE DRINK, VITAMIN GSH-S, and IMMUNE FORMULATION 200. These are among 3 currently registered trademarks in the portfolio.
What is THE PROIMMUNE COMPANY L.L.C.'s trademark registration success rate?
THE PROIMMUNE COMPANY L.L.C. has a 30% trademark registration rate, with 3 out of 10 resolved applications resulting in successful registration. Currently, 0 applications are pending review.